{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:29:34Z","timestamp":1789212574157,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,26]]},"DOI":"10.7759\/cureus.84821","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:42:02Z","timestamp":1748259722000},"source":"Crossref","is-referenced-by-count":4,"title":["Messenger Ribonucleic Acid (mRNA)-Based Universal Vaccines: Engineering Broad-Spectrum Immunity Against Future Pandemics"],"prefix":"10.7759","author":[{"given":"Joan  C","family":"Muodiaju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chidinma  S","family":"Madu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd1525","article-title":"Development and deployment of COVID-19 vaccines for those most vulnerable","volume":"13","author":"Koff WC","year":"2021","unstructured":"Koff WC, Schenkelberg T, Williams T, et al.. Development and deployment of COVID-19 vaccines for those most vulnerable. Sci Transl Med. 2021, 13:10.1126\/scitranslmed.abd1525","journal-title":"Sci Transl Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi N","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018, 17:261-79. 10.1038\/nrd.2017.243","journal-title":"Nat Rev Drug Discov"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi N","year":"2018","unstructured":"Pardi N, Hogan MJ, Naradikian MS, et al.. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018, 215:1571-88. 10.1084\/jem.20171450","journal-title":"J Exp Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin U","year":"2014","unstructured":"Sahin U, Karik\u00f3 K, T\u00fcreci \u00d6. mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov. 2014, 13:759-80. 10.1038\/nrd4278","journal-title":"Nat Rev Drug Discov"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary N","year":"2021","unstructured":"Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021, 20:817-38. 10.1038\/s41573-021-00283-5","journal-title":"Nat Rev Drug Discov"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3 K","year":"2005","unstructured":"Karik\u00f3 K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005, 23:165-75. 10.1016\/j.immuni.2005.06.008","journal-title":"Immunity"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier AJ","year":"2022","unstructured":"Barbier AJ, Jiang AY, Zhang P, et al.. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022, 40:840-54. 10.1038\/s41587-022-01294-2","journal-title":"Nat Biotechnol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2453304","article-title":"An mRNA vaccine candidate encoding cholera toxin subunit B and conserved antigens of influenza viruses confers cross-protection against influenza a viruses in adult and aged mice","volume":"21","author":"Xu L","year":"2025","unstructured":"Xu L, Yu Z, Xu Y, et al.. An mRNA vaccine candidate encoding cholera toxin subunit B and conserved antigens of influenza viruses confers cross-protection against influenza a viruses in adult and aged mice. Hum Vaccin Immunother. 2025, 21:2453304. 10.1080\/21645515.2025.2453304","journal-title":"Hum Vaccin Immunother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201800376","article-title":"Emerging technologies for low-cost, rapid vaccine manufacture","volume":"14","author":"Kis Z","year":"2019","unstructured":"Kis Z, Shattock R, Shah N, Kontoravdi C. Emerging technologies for low-cost, rapid vaccine manufacture. Biotechnol J. 2019, 14:e1800376. 10.1002\/biot.201800376","journal-title":"Biotechnol J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang Z","year":"2021","unstructured":"Wang Z, Schmidt F, Weisblum Y, et al.. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021, 592:616-22. 10.1038\/s41586-021-03324-6","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang X","year":"2022","unstructured":"Huang X, Kong N, Zhang X, et al.. The landscape of mRNA nanomedicine. Nat Med. 2022, 28:2273-87. 10.1038\/s41591-022-02061-1","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom K","year":"2021","unstructured":"Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021, 28:117-29. 10.1038\/s41434-020-00204-y","journal-title":"Gene Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay PF","year":"2020","unstructured":"McKay PF, Hu K, Blakney AK, et al.. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat Commun. 2020, 11:3523. 10.1038\/s41467-020-17409-9","journal-title":"Nat Commun"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/82_2020_202","article-title":"Messenger RNA-based vaccines against infectious diseases","volume":"440","author":"Alameh MG","year":"2022","unstructured":"Alameh MG, Weissman D, Pardi N. Messenger RNA-based vaccines against infectious diseases. Curr Top Microbiol Immunol. 2022, 440:111-45. 10.1007\/82_2020_202","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1567116","article-title":"Artificial intelligence in vaccine research and development: an umbrella review","volume":"16","author":"El Arab RA","year":"2025","unstructured":"El Arab RA, Alkhunaizi M, Alhashem YN, et al.. Artificial intelligence in vaccine research and development: an umbrella review. Front Immunol. 2025, 16:1567116. 10.3389\/fimmu.2025.1567116","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack FP","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al.. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020, 383:2603-15. 10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1917","article-title":"Vaccines against Middle East respiratory syndrome coronavirus for humans and camels","volume":"27","author":"Alharbi NK","year":"2017","unstructured":"Alharbi NK. Vaccines against Middle East respiratory syndrome coronavirus for humans and camels. Rev Med Virol. 2017, 27:10.1002\/rmv.1917","journal-title":"Rev Med Virol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn4955","article-title":"A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection","volume":"386","author":"Alameh MG","year":"2024","unstructured":"Alameh MG, Semon A, Bayard NU, et al.. A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection. Science. 2024, 386:69-75. 10.1126\/science.adn4955","journal-title":"Science"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181a00068","article-title":"Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients","volume":"32","author":"Weide B","year":"2009","unstructured":"Weide B, Pascolo S, Scheel B, et al.. Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients. J Immunother. 2009, 32:498-507. 10.1097\/CJI.0b013e3181a00068","journal-title":"J Immunother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan M","year":"2020","unstructured":"Yuan M, Wu NC, Zhu X, et al.. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020, 368:630-3. 10.1126\/science.abb7269","journal-title":"Science"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1016\/S0264-410X(00)00546-6","article-title":"The future of vaccines, immunisation concepts and practice","volume":"19","author":"Andr\u00e9 EF","year":"2001","unstructured":"Andr\u00e9 EF. The future of vaccines, immunisation concepts and practice. Vaccine. 2001, 19:2206-09.","journal-title":"Vaccine"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583077","article-title":"Emerging concepts and technologies in vaccine development","volume":"11","author":"Brisse M","year":"2020","unstructured":"Brisse M, Vrba SM, Kirk N, et al.. Emerging concepts and technologies in vaccine development. Front Immunol. 2020, 11:583077. 10.3389\/fimmu.2020.583077","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/359383-messenger-ribonucleic-acid-mrna-based-universal-vaccines-engineering-broad-spectrum-immunity-against-future-pandemics","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:42:02Z","timestamp":1748259722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/359383-messenger-ribonucleic-acid-mrna-based-universal-vaccines-engineering-broad-spectrum-immunity-against-future-pandemics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.84821","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,26]]}}}